N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 2081-2086

  Loureiro, Ana I ^a   Fernandes Lopes, Carlos ^a   Bonifácio, Maria João ^a   Wright, Lyndon C ^a   Soares da Silva, Patrício ^a,b  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b Inst of Pharmacol and Therapeutics   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; BIA 5 453; BIA 5 961; ETAMICASTAT; SULFADIMIDINE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSOL; DOG; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; FEMALE; HAMSTER; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MINIPIG; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; RAT; SPECIES DIFFERENCE;

ACETYLATION; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BENZOPYRANS; CRICETINAE; CYTOSOL; DOGS; DOPAMINE BETA-HYDROXYLASE; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; KINETICS; MACACA FASCICULARIS; MALE; MICE; RABBITS; RATS; SWINE; SWINE, MINIATURE;

EID: 84888623645     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053736     Document Type: Article

References (28)

1. Bonifácio MJ, Igreja B, Wright L, Soares-da-Silva P (2009) Kinetic studies on the inhibition of dopamine-β-hydroxylase by BIA 5-453 (Abstract). pA2 Online 7:050P.
2. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, and Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581-592.
3. Dorne JL (2004) Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 18:609-620.
4. Estrada L, Kanelakis KC, Levy GN, and Weber WW (2000) Tissue- and gender-specific expression of N-acetyltransferase 2 (Nat2*) during development of the outbred mouse strain CD-1. Drug Metab Dispos 28:139-146.
5. Gao W, Johnston JS, Miller DD, and Dalton JT (2006) Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2- hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase. Drug Metab Dispos 34:254-260.
6. Glinsukon T, Benjamin T, Grantham PH, Weisburger EK, and Roller PP (1975) Enzymic N-acetylation of 2,4-toluenediamine by liver cytosols from various species. Xenobiotica 5:475-483.
7. Grant DM, Blum M, Beer M, and Meyer UA (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
8. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, and Feng Y (2000a) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29-42.
9. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, and Weber WW (2000b) Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 28:1425-1432.
10. Husain A, Zhang X, Doll MA, States JC, Barker DF, and Hein DW (2007) Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35:721-727.
11. Igreja B, Pires NM, Wright L, and Soares-da-Silva P (2008) Effect of combined administration of BIA 5-453 and captopril on blood pressure and heart rate (Abstract). Hypertension 52:E62.
12. Igreja B, Pires NM, Wright LC, and Soares-da-Silva P (2011) Antihypertensive effects of a selective peripheral dopamine beta-hydroxylase inhibitor alone or in combination with other antihypertensive drugs [Abstract]. Hypertension 58:E161-E162.
13. Levy GN, Martell KJ, DeLeon JH, and Weber WW (1992) Metabolic, molecular genetic and toxicological aspects of the acetylation polymorphism in inbred mice. Pharmacogenetics 2:197-206.
14. Mahmood I, Green MD, and Fisher JE (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692-697.
15. Meyer UA (1994) Polymorphism of human acetyltransferases. Environ Health Perspect 102 (Suppl 6):213-216.
16. Nunes T, Rocha JF, Vaz-da-Silva M, Falcão A, Almeida L, and Soares-da-Silva P (2011) Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. Clin Ther 33:776-791.
17. Nunes T, Rocha JF, Vaz-da-Silva M, Igreja B, Wright LC, Falcão A, Almeida L, and Soares-da-Silva P (2010) Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D 10:225-242.
18. Otsuka M, Furuuchi S, Usuki S, Nitta S, and Harigaya S (1983) Metabolism of afloqualone, a new centrally acting muscle relaxant, in monkeys and dogs. J Pharmacobiodyn 6:708-720.
19. Rocha JF, Vaz-da-Silva M, Nunes T, Igreja B, Loureiro AI, Bonifácio MJ, Wright LC, Falcão A, Almeida L, and Soares-da-Silva P (2011) Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine beta-hydroxylase inhibitor, in healthy subjects. J Clin Pharmacol 52:156-170.
20. Savidge RD, Bui KH, Birmingham BK, Morse JL, and Spreen RC (1998) Metabolism and excretion of zafirlukast in dogs, rats, and mice. Drug Metab Dispos 26:1069-1076.
21. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, and Wrighton SA (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
22. Spielberg SP (1996) N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 24:509-519.
23. Stanley LA and Sim E (2008) Update on the pharmacogenetics of NATs: structural considerations. Pharmacogenomics 9:1673-1693.
24. Stevens GJ, Payton M, Sim E, and McQueen CA (1999) N-acetylation of the heterocyclic amine batracylin by human liver. Drug Metab Dispos 27:966-971.
25. Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol 64:170-179.
26. Vaz-da-Silva M, Nunes T, Rocha JF, Falcão A, Almeida L, and Soares-da-Silva P (2011) Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453). Drugs R D 11:127-136.
27. Walraven JM, Trent JO, and Hein DW (2008) Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1. Drug Metab Rev 40:169-184.
28. Winter HR and Unadkat JD (2005) Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos 33:969-976.